- Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim update expected in first quarter results conference call. NSCLC Phase 2 interim update expected in first half 2022.
- Ozuriftamab vedotin (BA3021) continues with enrollment of patients in Phase 2 clinical studies in NSCLC and melanoma. Expect mid-year initial interim update for NSCLC and melanoma. Phase 2 study in Head and Neck cancer has been initiated.
- CAB-CTLA-4 Phase 1/2 clinical trial (BA3071) addressing multiple solid tumor indications has been initiated.
- IND filings for four CAB bispecific and antibody drug conjugate product candidates expected in 2022 through end of 2023.
- Cash balance of $245 million at year end 2021 will fund planned operations including all current product development programs into first half of 2024.
PR Newswire
SAN DIEGO, March 1, 2022
